U.S. Patient and Trademark Reduction Act of 1985, no persons are required to responsed to a collection of information unless of spinoses, and office of the paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless of displays avail OMED

For Use of Neurokinin Antagonists In The Treatment of Urinary Incontinence  Art Unit 1614 Examiner Spivack, Phyllis G.  This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified	
Application Number 10/576,052 Filed 26 October 2004  For Use of Neurokinin Antagonists In The Treatment of Urinary Incontinence  Art Unit 1614 Examiner Spivack, Phyllis G.  This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified	
For Use of Neurokinin Antagonists In The Treatment of Urinary Incontinence  Art Unit 1614 Examiner Spivack, Phyllis G.  This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified	
Art Unit 1614 Examiner SpIVack, Phyllis G.  This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified	
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified	
application.	
The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):	- 1
Fee Small Entity Fee	
One month (37 CFR 1.17(a)(1)) \$120 \$60 \$	-
Two months (37 CFR 1.17(a)(2)) \$460 \$230 \$	-
✓ Three months (37 CFR 1.17(a)(3)) \$1050 \$525 \$ 1050	-
Four months (37 CFR 1.17(a)(4)) \$1640 \$820 \$	-
Five months (37 CFR 1.17(a)(5)) \$2230 \$1115 \$	-
Applicant claims small entity status. See 37 CFR 1.27.	
A check in the amount of the fee is enclosed.	
Payment by credit card. Form PTO-2038 is attached.	
The Director has already been authorized to charge fees in this application to a Deposit Account.	
The Director is hereby authorized to charge any fees which may be required, or credit any overpayment Deposit Account Number 50-2424	to
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
I am the applicant/inventor.	İ
assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96).	
attorney or agent of record. Registration Number 37,276	
attorney or agent under 37 CFR 1.34.  Registration number if acting under 37 CFR 1.34	
Galut A Hall Sept. 19, 2008	
Sighature Date	
Robert R. Axenfeld 215-772-7691	
Typed or printed name Telephone Number	- 1
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more the signature is required, see below.	n one
Total of forms are submitted.	

This collection of information is required by 37 CPR 1.136(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO) to process) an application. Confidentially is governed by 39 USC. 122 and 37 CPR 1.11 and 14. This collection is estimated to false for minutes to complete including galbering, preparing, and submitting the completed application form to the USPTO. Time will very depending, upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for describing this surface, should be sent to the Chief Information Officer, US. Patent and Technary. Office. US. Department of Commerce, P.O. Dox 1450, Alexandria. V. 2 2213-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.